Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma

Chinese Medical Journal (Taipei)

Volumn 63, Issue 3, 2000, Pages 220-225

  Wang, Peng Hui ^a,b   Yuan, Chiou Chung ^a,b   Shyong, Wen Yuann ^a,b   Chiang, Shu Chiung ^a,b   Chao, Jing Yi ^a,b   Yen, Ming Shyen ^a,b   Ng, Heung Tat ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Epithelial ovarian carcinoma; FIGO IIIC; Optimal debulking surgery; Prognosis

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN;

ABDOMINAL HYSTERECTOMY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; FOLLOW UP; HUMAN; LYMPHADENECTOMY; OVARY CARCINOMA; PARAAORTIC LYMPH NODE; PROGNOSIS; SALPINGOOOPHORECTOMY;

CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0034023291     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: DiSaia PJ, Creasman WT, eds. Clinical Gynecologic Oncology, 5th ed. St. Louis: Mosby-Year Book, 1997: 282-350.
2. Rosen AC, Sevelda P, Klein M, Graf AH, Lahousen M, Reiner L, et al. A comparative analysis of management and prognosis in stage I and II fallopian tube carcinoma and epithelial ovarian cancer. Br J Cancer 1994;69:577-9.
3. Hoskins WJ, Lawton FG. Primary cytoreductive surgery for advanced-stage disease. In: Gershenson DM, McGuire WP, eds. Ovarian Cancer. Controversies in Management. New York: Churchill Livingstone, 1998:65-84.
4. McGuire WP, Hoskins WJ, Brady MF, Kucera PK, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
5. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 2nd ed. Philadelphia: Lippincott-Raven Press, 1997;919-86.
6. SAS/STAT User's Guide, Release 6.12 Edition. Cary (NC): SAS Institute, 1994.
7. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1986;4:57-81.
8. Mantel N. Evaluation of survival data and two rank-order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
9. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34:187-220.
10. Chang PY. Cancer Registry Annual Report, ROC. Taipei: Department of Health ROC, 1996;45-6.
11. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of the largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170:974-9.
12. Eisenkop SM, Nalick RH, Wang HJ, Teng NN. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993;51: 224-9.
13. Omura GA, Bundy B, Berek J, Curry S, Delgado G, Mortel R. Randomized tnal of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989;7: 457-65.
14. Griffiths CT. Surgical resection of the tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
15. Griffiths CT. Surgery at the time of diagnosis in ovarian cancer. In: Blackledge G, Chan KK, eds. Management of Ovarian Cancer. Butterworths: London, 1986;60-78.
16. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat Reports 1979;63:1727-33.
17. Morton DL. Changing concepts in cancer surgery: surgery as immunotherapy. Am J Surg 1978; 135:767-71.
18. Brinkhuis M, Meijer GA, Baak JP. An evaluation of prognostic factors in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1995;63:115-24.
19. McGuire WP, Hoskins WJ, Brady MF, Kucera PK, Partridge EE, Look KY, et al. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage in and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol 1997;24(Suppl):13-6.
20. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
21. Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, et al. Predictive factors for long term survival in patients with advanced ovarian cancer. Gynecol Oncol 1989;34:88-93.
22. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decke DG, et al. Adjuvant therapy in stage I and II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990;322:1021-7.
23. Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, eds. Practical Gynecologic Oncology, 2nd ed. Baltimore: Williams & Wilkins, 1994;327-75.
24. Wang PH, Yuan CC, Chao HT, Yen MS, Ng HT. Outcome of the advanced primary fallopian tube adenocarcinoma. Chin Med J (Taipei): 1999;62:782-6.
25. Biersack HJ, Bender H, Ruhlmann J, Schomburg A, Grunwald F. FDG-PET in clinical oncology: review and evaluation of results of a private clinical PET center. In: Freeman LM, ed. Nuclear Medicine Annual 1997. Philadelphia: Lippincott-Raven Press, 1997;1-30.
26. Yuan CC, Liu RS, Wang PH, Ng HT, Yeh SH. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma: an initial report. J Reprod Med 1999;44:775-8.